Our co-directors, Michel Goldman and Mathias Dewatripont have recently published two articles in Le Monde where they argue that public trust is the backbone of any immunization strategy and discuss the economic impact of lockdowns.
The world’s first mRNA vaccine has begun its rollout after being produced at unprecedented speed as part of the global effort to end the Covid-19 pandemic. In trials these vaccines have shown to be at least 94% effective at preventing people from falling ill with Covid-19. But how safe is this new technology?
In an interview given to Horizon: the EU Research & Innovation magazine our co-director, Michel Goldman sheds light on five key facts about the mRNA vaccines.